"Men"

This is the best way to prevent blood clots.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

Warning: If you have 4 symptoms in your eye, don't take them seriously, they are precursors to retinal detachment

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

Anemia is a very common problem among women. Anemia makes people less resistant and depressed, and serious anemia can also endanger the health of the body, so when the situation of anemia occurs, it should be promptly adjusted. The actual fact is that you will be able to get a lot more than just a few of the most popular and popular items.

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.

Cervical cancer is one of the most common gynecological malignancies. Its incidence rate is second only to endometrial cancer worldwide, and it ranks first in developing countries and regions. According to statistics, there are 450000 new cases of cervical cancer worldwide every year. The occurrence and development of cervical cancer usually go through a relatively long process, so it is possible to prevent this disease.